BioCentury
ARTICLE | Clinical News

AZD5363: Phase I data

April 15, 2013 7:00 AM UTC

Data from a pair of open-label, dose-escalation, European and Japanese Phase I trials in a total of 92 patients showed that twice-daily oral AZD5363 led to 2 partial responses - 1 ovarian cancer patie...